Khorana Risk Score for VTE in Cancer Patients
The Khorana Risk Score identifies ambulatory cancer patients starting chemotherapy who are at increased risk for venous thromboembolism.
Indications d'utilisation
Used in ambulatory cancer patients starting systemic therapy to estimate 6‑month VTE risk and identify those with score ≥2 who may benefit from prophylaxis. Validated across multiple cohorts and used in trials such as AVERT (apixaban reduced VTE 4.2% vs 10.2% 1 [Level I evidence]). Guides selective prophylaxis per ASCO/ESMO recommendations and supports patient counseling on individualized VTE risk.
Informations et précautions
Identifies higher VTE risk in chemotherapy outpatients but has modest discrimination and poor performance in several cancers (lung, pancreatic, hepatobiliary) 1. High‑risk groups (≥3) show clearer benefit from prophylaxis, supported by LMWH/DOAC trials (e.g., apixaban HR 0.41) 2. Avoid overreliance—many VTEs occur outside high‑risk strata 3. Use with caution in patients with high bleeding risk.